Skip to main content
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1992 Dec;36(12):2736–2740. doi: 10.1128/aac.36.12.2736

Cure of murine Trypanosoma brucei rhodesiense infections with an S-adenosylmethionine decarboxylase inhibitor.

C J Bacchi 1, H C Nathan 1, N Yarlett 1, B Goldberg 1, P P McCann 1, A J Bitonti 1, A Sjoerdsma 1
PMCID: PMC245537  PMID: 1482141

Abstract

The compound 5'-([(Z)-4-amino-2-butenyl]methylamino)-5'-deoxyadenosine (MDL73811), a potent inhibitor of S-adenosylmethionine decarboxylase, was effective in mice against six of eight clinical isolates of Trypanosoma brucei rhodesiense, the causative agent of East African sleeping sickness. In combination with the ornithine decarboxylase inhibitor DL-alpha-difluoromethylornithine (DFMO; Ornidyl), MDL73811 acted synergistically to cure seven of eight infections. MDL73811 was effective when given singly at 50 to 100 mg/kg of body weight per day for 7 days (osmotic pumps). In combination with subcurative DFMO levels (0.25 to 1.0% in drinking water for 7 days), the curative MDL73811 dose could be lowered to 25 or 50 mg/kg, depending on the isolate. Oral administration of the MDL73811-DFMO combination was also effective in an acute infection and in a long-term central nervous system model of Trypansoma brucei brucei infection. These data indicate that MDL73811 may be effective therapeutically in drug-refractory and late-stage East African trypanosomiasis.

Full text

PDF
2738

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bacchi C. J., Nathan H. C., Clarkson A. B., Jr, Bienen E. J., Bitonti A. J., McCann P. P., Sjoerdsma A. Effects of the ornithine decarboxylase inhibitors DL-alpha-difluoromethylornithine and alpha-monofluoromethyldehydroornithine methyl ester alone and in combination with suramin against Trypanosoma brucei brucei central nervous system models. Am J Trop Med Hyg. 1987 Jan;36(1):46–52. doi: 10.4269/ajtmh.1987.36.46. [DOI] [PubMed] [Google Scholar]
  2. Bacchi C. J., Nathan H. C., Livingston T., Valladares G., Saric M., Sayer P. D., Njogu A. R., Clarkson A. B., Jr Differential susceptibility to DL-alpha-difluoromethylornithine in clinical isolates of Trypanosoma brucei rhodesiense. Antimicrob Agents Chemother. 1990 Jun;34(6):1183–1188. doi: 10.1128/aac.34.6.1183. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Bacchi C. J., Sufrin J. R., Nathan H. C., Spiess A. J., Hannan T., Garofalo J., Alecia K., Katz L., Yarlett N. 5'-Alkyl-substituted analogs of 5'-methylthioadenosine as trypanocides. Antimicrob Agents Chemother. 1991 Jul;35(7):1315–1320. doi: 10.1128/aac.35.7.1315. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Bales J. D., Jr, Harrison S. M., Mbwabi D. L., Schecter P. J. Treatment of arsenical refractory Rhodesian sleeping sickness in Kenya. Ann Trop Med Parasitol. 1989 Aug;83 (Suppl 1):111–114. doi: 10.1080/00034983.1989.11812414. [DOI] [PubMed] [Google Scholar]
  5. Bitonti A. J., Byers T. L., Bush T. L., Casara P. J., Bacchi C. J., Clarkson A. B., Jr, McCann P. P., Sjoerdsma A. Cure of Trypanosoma brucei brucei and Trypanosoma brucei rhodesiense infections in mice with an irreversible inhibitor of S-adenosylmethionine decarboxylase. Antimicrob Agents Chemother. 1990 Aug;34(8):1485–1490. doi: 10.1128/aac.34.8.1485. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Byers T. L., Bush T. L., McCann P. P., Bitonti A. J. Antitrypanosomal effects of polyamine biosynthesis inhibitors correlate with increases in Trypanosoma brucei brucei S-adenosyl-L-methionine. Biochem J. 1991 Mar 1;274(Pt 2):527–533. doi: 10.1042/bj2740527. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Clarkson A. B., Jr, Bienen E. J., Bacchi C. J., McCann P. P., Nathan H. C., Hutner S. H., Sjoerdsma A. New drug combination for experimental late-stage African trypanosomiasis: DL-alpha-difluoromethylornithine (DFMO) with suramin. Am J Trop Med Hyg. 1984 Nov;33(6):1073–1077. doi: 10.4269/ajtmh.1984.33.1073. [DOI] [PubMed] [Google Scholar]
  8. Hoffman R. M. Altered methionine metabolism and transmethylation in cancer. Anticancer Res. 1985 Jan-Feb;5(1):1–30. [PubMed] [Google Scholar]
  9. Jennings F. W., Gray G. D. Relapsed parasitaemia following chemotherapy of chronic T. brucei infections in mice and its relation to cerebral trypanosomes. Contrib Microbiol Immunol. 1983;7:147–154. [PubMed] [Google Scholar]
  10. Jennings F. W., Whitelaw D. D., Urquhart G. M. The relationship between duration of infection with Trypanosoma brucei in mice and the efficacy of chemotherapy. Parasitology. 1977 Oct;75(2):143–153. doi: 10.1017/s0031182000062284. [DOI] [PubMed] [Google Scholar]
  11. Mamont P. S., Danzin C., Wagner J., Siat M., Joder-Ohlenbusch A. M., Claverie N. Accumulation of decarboxylated S-adenosyl-L-methionine in mammalian cells as a consequence of the inhibition of putrescine biosynthesis. Eur J Biochem. 1982 Apr;123(3):499–504. doi: 10.1111/j.1432-1033.1982.tb06559.x. [DOI] [PubMed] [Google Scholar]
  12. Mamont P. S., Joder-Ohlenbusch A. M., Nussli M., Grove J. Indirect evidence for a strict negative control of S-adenosyl-L-methionine decarboxylase by spermidine in rat hepatoma cells. Biochem J. 1981 May 15;196(2):411–422. doi: 10.1042/bj1960411. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Nathan H. C., Bacchi C. J., Hutner S. H., Rescigno D., McCann P. P., Sjoerdsma A. Antagonism by polyamines of the curative effects of alpha-difluoromethylornithine in Trypanosoma brucei brucei infections. Biochem Pharmacol. 1981 Nov 1;30(21):3010–3013. doi: 10.1016/0006-2952(81)90270-7. [DOI] [PubMed] [Google Scholar]
  14. Pegg A. E. Polyamine metabolism and its importance in neoplastic growth and a target for chemotherapy. Cancer Res. 1988 Feb 15;48(4):759–774. [PubMed] [Google Scholar]
  15. Penketh P. G., Shyam K., Divo A. A., Patton C. L., Sartorelli A. C. Methylating agents as trypanocides. J Med Chem. 1990 Feb;33(2):730–732. doi: 10.1021/jm00164a041. [DOI] [PubMed] [Google Scholar]
  16. Ueland P. M. Pharmacological and biochemical aspects of S-adenosylhomocysteine and S-adenosylhomocysteine hydrolase. Pharmacol Rev. 1982 Sep;34(3):223–253. [PubMed] [Google Scholar]
  17. Yarlett N., Bacchi C. J. Effect of DL-alpha-difluoromethylornithine on methionine cycle intermediates in Trypanosoma brucei brucei. Mol Biochem Parasitol. 1988 Jan 1;27(1):1–10. doi: 10.1016/0166-6851(88)90019-9. [DOI] [PubMed] [Google Scholar]
  18. Yarlett N., Goldberg B., Nathan H. C., Garofalo J., Bacchi C. J. Differential sensitivity of Trypanosoma brucei rhodesiense isolates to in vitro lysis by arsenicals. Exp Parasitol. 1991 Feb;72(2):205–215. doi: 10.1016/0014-4894(91)90138-m. [DOI] [PubMed] [Google Scholar]
  19. Yarlett N., Quamina A., Bacchi C. J. Protein methylases in Trypanosoma brucei brucei: activities and response to DL-alpha-difluoromethylornithine. J Gen Microbiol. 1991 Mar;137(3):717–724. doi: 10.1099/00221287-137-3-717. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES